The Food and Drug Administration has approved a controversial new drug for the fatal condition known as ALS, or Lou Gehrig's disease. The decision is being hailed by patients and their advocates, but questioned by some scientists.
of just 137 patients. Results suggested the drug might extend patients' lives by five to six months, or more.
"I totally understand why people would be trying to figure out a way to get this to patients," he says."There's just a general concern out there that maybe the trial is wrong." The second vote came after Dr. Billy Dunn, director of the FDA's Office of Neuroscience, encouraged the committee to exercise"flexibility" when considering a drug that might help people facing certain death.A negative result from that study would be a major blow to Amylyx and ALS patients.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Carlos Pacheco, Suffering From ALS, Posts His Final Comics CoverCarlos Pacheco is a Spanish comic book creator, best known in the US for comic books such as Avengers Forever, X-Men, Superman, Fantastic Four, Green
Les mer »
FDA approves ALS drug whose study was partly funded by Ice Bucket Challenge | CNNThe US FDA has approved a new ALS drug that was backed by patients and advocacy groups. Its study had been partly funded by the viral Ice Bucket Challenge.
Les mer »
ALS drug gets FDA approval despite uncertainty about effectiveness | CNNThe FDA has approved a new ALS drug that was backed by patients and advocacy groups. Its study had been partly funded by the viral Ice Bucket Challenge.
Les mer »
Amylyx’s ALS Drug Is Approved by the FDARelyvrio, a new drug to treat ALS, has been approved by the FDA, giving patients a new option that may slow progression of the fatal degenerative disease
Les mer »
ALS drug wins FDA approval despite questionable dataWASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Les mer »